Menu
Back to Journals » Pharmacogenomics and Personalized Medicine » Volume 12
Precision medicine approaches for the management of Ewing sarcoma: current perspectives
Authors Rizk VT, Walko CM, Brohl AS
Received 31 October 2018
Accepted for publication 29 December 2018
Published 17 January 2019 Volume 2019:12 Pages 9—14
DOI https://doi.org/10.2147/PGPM.S170612
Checked for plagiarism Yes
Review by Single-blind
Peer reviewer comments 3
Editor who approved publication: Dr Martin Bluth
Victoria T Rizk,1 Christine M Walko,2 Andrew S Brohl3,4
1University of South Florida Hematology/Oncology Fellowship, 2DeBartolo Family Personalized Medicine Institute, 3Sarcoma Department, 4Chemical Biology and Molecular Medicine Program, H. Lee Moffitt Cancer Center and Research Institute, Tampa, FL, USA
Abstract: Advancements in molecular and genetic techniques have significantly furthered our biological understanding of Ewing sarcoma (ES). ES is typified by a driving TET–ETS fusion with an otherwise relatively quiet genome. Detection of one of several characteristic fusions, most commonly EWSR1–FLI1, is the gold standard for diagnosis. We discuss the current role of precision medicine in the diagnosis, treatment, and monitoring of ES. Continued efforts toward molecularly guided approaches are actively being pursued in ES to better refine prognosis, identify germline markers of disease susceptibility, influence therapeutic selection, effectively monitor disease activity in real time, and identify genetic and immunotherapeutic targets for therapeutic development.
Keywords: Ewing sarcoma, next generation sequencing, genomics, liquid biopsy, targeted therapy
This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License.
By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.